Immunome Secures Additional $4.3M Funding From DoD To Develop COVID-19 Antibody Cocktail

• Immunome Inc (NASDAQ: IMNM) has secured additional funding of $4.3 million from the Department of Defense (DoD) for the development of an antibody cocktail (IMM-BCP-01) to combat SARS-CoV-2 and its variants.

• The additional capital comes less than a year after an initial DOD award of $13.3 million, bringing the total commitment to Immunome to $17.6 million.

• The additional funding is to support the expansion of the clinical study following feedback from the FDA.

• IND filing for IMM-BCP-01 is expected in late 2Q/early 3Q of 2021.

• IMM-BCP-01 contains three monoclonal antibodies that bind to non-overlapping regions of the spike protein with picomolar affinity. The antibodies exhibit combinatorial effects in vitro against multiple SARS-CoV-2 variants.

• Price Action: IMNM shares are up 1.09% at $18.30 on the last check Thursday.

See more from Benzinga

• Click here for options trades from Benzinga

• Omeros's Narsoplimab US Application Review Pushed By 3 Months, Shares Drop

• PDS Biotech's Triplet Therapy Shows Clinical Activity In Advanced HPV-Associated Malignancies

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.